Palmitoyl-L-carnitine (PC), an ischemic metabolite, causes cellular Na ϩ and Ca 2ϩ overload and cardiac dysfunction. This study determined whether ranolazine [(Ϯ)-1-piperazineacetamide, N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]Ϫ] attenuates PC-induced Na ϩ current and ventricular contractile dysfunction of the isolated heart. PC (4 M, 30 min) increased late Na ϩ current by 1034 Ϯ 349% in guinea pig isolated ventricular myocytes; ranolazine (10 M) and tetrodotoxin (TTX, 3 M) significantly attenuated this effect of PC. PC increased left ventricular end-diastolic pressure (LVEDP), coronary perfusion pressure (CPP), wall stiffness, and cardiac lactate and adenosine release from the isolated heart. Ranolazine (10 M) significantly reduced the PC-induced increase in LVEDP by 72 Ϯ 6% (n ϭ 6, p Ͻ 0.001), reduced left ventricular wall stiffness, and attenuated the PC-induced increase of CPP by 53 Ϯ 10% (n ϭ 6 -7, p Ͻ 0.05). Ranolazine (10 M) reduced the PC-induced increases of lactate and adenosine release by 70 Ϯ 8 and 81 Ϯ 5%, respectively (n ϭ 6, p Յ 0.05 for both). TTX (2 M) significantly (p Ͻ 0.05) reduced PC-induced increases of CPP and LVEDP. Pretreatment of isolated myocytes or hearts with the free radical scavenger tiron (4,5-dihydroxy-1,3-benzenedisulfonic acid, disodium salt) (1 mM) significantly reduced the effects of PC to cause increases of late Na ϩ current and LVEDP, respectively, but unlike ranolazine or TTX, tiron did not reverse increases of late Na ϩ current and LVEDP caused by PC. In summary, ranolazine and TTX, inhibitors of the late Na ϩ current, attenuated the PC-induced ventricular contractile dysfunction and increase of coronary resistance in the guinea pig isolated heart. Long-chain acyl carnitines, including palmitoyl-L-carnitine (PC), are intermediates of fatty acid metabolism that accumulate rapidly during brief ischemia (Sobel et al., 1978; DaTorre et al., 1991) , secondary to a reduction of tissue oxygenation and mitochondrial lipid oxidation. Hypoxia of 1-h duration was shown to increase the content of long-chain acylcarnitines in sarcolemmal membranes of cultured neonatal rat cardiac myocytes by 70-fold (Knabb et al., 1986) . PC has been shown to cause metabolic, electrical, and mechanical cardiac malfunction (Corr et al
by 53 Ϯ 10% (n ϭ 6 -7, p Ͻ 0.05). Ranolazine (10 M) reduced the PC-induced increases of lactate and adenosine release by 70 Ϯ 8 and 81 Ϯ 5%, respectively (n ϭ 6, p Յ 0.05 for both). TTX (2 M) significantly (p Ͻ 0.05) reduced PC-induced increases of CPP and LVEDP. Pretreatment of isolated myocytes or hearts with the free radical scavenger tiron (4,5-dihydroxy-1,3-benzenedisulfonic acid, disodium salt) (1 mM) significantly reduced the effects of PC to cause increases of late Na ϩ current and LVEDP, respectively, but unlike ranolazine or TTX, tiron did not reverse increases of late Na ϩ current and LVEDP caused by PC. In summary, ranolazine and TTX, inhibitors of the late Na ϩ current, attenuated the PC-induced ventricular contractile dysfunction and increase of coronary resistance in the guinea pig isolated heart. Long-chain acyl carnitines, including palmitoyl-L-carnitine (PC), are intermediates of fatty acid metabolism that accumulate rapidly during brief ischemia (Sobel et al., 1978; DaTorre et al., 1991) , secondary to a reduction of tissue oxygenation and mitochondrial lipid oxidation. Hypoxia of 1-h duration was shown to increase the content of long-chain acylcarnitines in sarcolemmal membranes of cultured neonatal rat cardiac myocytes by 70-fold (Knabb et al., 1986) . PC has been shown to cause metabolic, electrical, and mechanical cardiac malfunction (Corr et al., 1979; Sakata et al., 1989; Sato et al., 1992 Sato et al., , 1993 Tanaka et al., 1992; Wu and Corr, 1992 Allely et al., 1993; Shen and Pappano, 1995; Hara et al., 1997; Netticadan et al., 1999; Maruyama et al., 2000) . PC alters ion channel function and has been reported to decrease I Ca,L (Wu and Corr, 1992) , reduce the open probability of the inward rectifier K ϩ current I K1 (Sato et al., 1993) , inhibit I KATP (Haruna et al., 2000) , and reduce peak I Na (Sato et al., 1992) . PC concentration-and time-dependently increased and then decreased the duration of the action potential of the guinea pig ventricular myocyte (Mészà ros and Pappano, 1990; Shen and Pappano, 1995) , induced Ca 2ϩ overload, I Ti , and aftercontractions, and both early and late afterdepolarizations (Meszaros and Pappano, 1990; Wu and Corr, 1992; Shen and Pappano, 1995) . Palmitoyl-L-carnitine also induced a slowly inactivating Na ϩ -sensitive current and increased [Na ϩ ] i (Wu and Corr, 1995) in guinea pig ventricular myocytes. This latter finding suggests that palmitoyl-L-carnitine may increase the late (persistent) Na ϩ current (late I Na ) in ventricular myocytes. An increase of late I Na in the heart is known to lead to Na ϩ and Ca 2ϩ overload and both electrical and mechanical dysfunction (Ver Donck et al., 1993; Hale et al., 2008) . Several agents are reported to attenuate the toxic effects of PC on the isolated heart: the Na ϩ channel blockers tetrodotoxin (TTX) and dilazep , the Na ϩ /H ϩ exchange inhibitor 5-(N,N-dimethyl)-amiloride (Arakawa and Hara, 1999) , and the local anesthetic, lidocaine . These findings suggest that inhibition of Na ϩ channels and reduction of sodium overload are beneficial to reduce PC-induced dysfunction. The antianginal and anti-ischemic drug ranolazine (Siddiqui and Keam, 2006; Hale et al., 2008) was also reported to attenuate PC-induced mechanical and metabolic derangement in the rat isolated heart (Allely et al., 1993; Maruyama et al., 2000) . More recently, it was discovered that ranolazine inhibits late I Na and cellular Na ϩ and Ca 2ϩ overload in the heart (Antzelevitch et al., 2004; Belardinelli et al., 2006) . These findings suggest that enhancement of late I Na , which is normally a very small current in cardiac myocytes, may explain many of the effects of PC on the heart and that inhibition of late I Na is the mechanism by which ranolazine acts to attenuate PC-induced dysfunction. The present study was designed to test this hypothesis. We determined whether PC increases late I Na , whether the effect of PC to increase late I Na is reversed by ranolazine and by TTX, and whether ranolazine attenuates PC-induced diastolic dysfunction (increased wall stiffness, reduced vascular conductance and ischemia) of the heart. Furthermore, because ranolazine has been reported to be an antagonist of ␤-adrenergic receptors in rat heart (Lé-tienne et al., 2001) , increase myocardial blood flow during exposure to PC (Maruyama et al., 2000) , attenuate the effects of reactive oxygen species (Song et al., 2006) , and inhibit the hERG K ϩ current in the heart (Antzelevitch et al., 2004) , we sought to clarify the potential roles of these actions as mechanisms of ranolazine's effect to reduce the toxicity of PC. Guinea pig isolated hearts and single ventricular myocytes were used in these studies.
Materials and Methods

Isolation, Perfusion, and Recording of Function of the Guinea Pig Heart
Female Dunkin-Hartley guinea pigs, weighing between 300 and 400 g, were used for all experiments. Animal use was approved by the Institutional Animal Care and Use Committee of CV Therapeutics (isolated heart studies) or of the University of Florida (myocyte electrophysiology) and conformed to the Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources, 1996) . Guinea pigs were anticoagulated by injection of heparin (100 U/kg i.m.) and anesthetized with an intramuscular injection of ketamine/xylazine (48/6.4 mg/kg, respectively). The heart was excised and placed in oxygenated Krebs-Henseleit (K-H) buffer at room temperature. The aorta was rapidly cannulated and perfused in a retrograde manner to maintain a constant flow of 10 ml/min with K-H solution at 37 Ϯ 2°C using a Langendorff apparatus. Hearts were paced at a rate of 4 Hz. The contents of the K-H solution were 118 mM NaCl, 4.8 mM KCl, 1.2 mM KH 2 PO 4 , 2.5 mM CaCl 2 , 1.2 mM MgSO 4 , 2 mM pyruvic acid, 5.5 mM glucose, 0.5 mM Na 2 EDTA, and 25 mM NaHCO 3 . K-H solution was continuously bubbled with 95% O 2 /5% CO 2 , and pH was adjusted to 7.4 with 5 N NaOH. To measure coronary perfusion pressure (CPP), a pressure transducer was connected to the aortic cannula via a side port of the cannula positioned above the level of the heart. To measure left ventricular end-diastolic pressure (LVEDP), a water-filled custom-made balloon of latex film was attached to a small-diameter polyethylene catheter and inserted through an incision in the left atrium, across the mitral valve, and into the LV. The polyethylene catheter was connected to a pressure transducer (BIOPAC Systems, Inc., Goleta, CA), and the balloon was inflated to achieve an LVEDP of 5 to 8 mm Hg. Balloon volume was kept constant through an experiment unless otherwise indicated. To measure left ventricular wall stiffness, LVEDP was measured in response to incremental increases in the volume of the intraventricular balloon. Hearts were perfused for 20 min without intervention or until coronary perfusion pressure was stabilized before beginning an experiment.
Drugs and Solutions
Palmitoyl-L-carnitine, sodium nitroprusside, adenosine, acetylcholine, the hERG current blocker E-4031, and DMSO were purchased from Sigma-Aldrich (St. Louis, MO). The ␤-adrenergic receptor blocker esmolol hydrochloride (Paddock Laboratories, Minneapolis, MN) was purchased from a local pharmacy. Ranolazine (Siddiqui and Keam, 2006) and the A 2A -adenosine receptor agonist CVT-3146 were synthesized by the Department of Medicinal and Bio-Organic Chemistry, CV Therapeutics, Inc. TTX was purchased from EMD Biosciences (San Diego, CA), and lactate assay kits were purchased from BioVision (Mountain View, CA). To prepare stock solutions, palmitoyl-L-carnitine, ranolazine, CVT-3146, adenosine, and acetylcholine were dissolved at a concentration of 10 mM in DMSO. Sodium nitroprusside and the free-radical scavenger tiron (4,5-dihydroxy-1,3-benzenedisulfonic acid, disodium salt) were dissolved in water to achieve concentrations of 10 mM and 1 M, respectively. All DMSO stock solutions were further diluted 1:1000 or greater in the cardiac perfusate on the day of an experiment.
Experimental Protocols Using Isolated Hearts
Control (drug-free) records of CPP and LVEDP were obtained after stabilization. To determine the effects of PC in the absence and presence of drugs, two protocols were used. In the first, hearts were perfused with PC (4 M) for 30 min, followed by a 30-min washout of PC in the presence of either vehicle or drug. The effect of drug to reverse PC-induced dysfunction was measured. In a second protocol, the effect of drug to prevent the actions of PC was determined, and treatment drug was administered 10 min before exposure of the heart to PC. In both protocols, measurements of CPP and LVEDP were recorded at intervals of 10 min. In some experiments using both protocols, samples of the cardiac effluent were obtained at 10-min intervals to determine lactate release by the heart. Using the first protocol, adenosine release was determined by collection of effluent samples for 1 min at the single time point of 60 min (i.e., after 30-min treatment with PC and 30-min washout of PC in the presence of either vehicle or ranolazine).
Determination of Cardiac Effluent Concentrations of Lactic Acid and Adenosine
Samples (approximately 2 ml) of cardiac effluent were collected at selected times and stored at Ϫ20°C until they were thawed and analyzed. Lactic acid content of samples was determined using a commercial kit (BioVision). Adenosine content of samples was determined by the Preclinical Development Group at CV Therapeutics using liquid chromatography followed by mass spectrometry. min; and 3) Ca 2ϩ -free solution containing collagenase (120 units/ml) and albumin (2 mg/ml), for 20 min. At the end of the perfusion, the ventricles were minced and gently shaken for 10 min in solution 3 to release single myocytes for study.
Electrophysiological Recording. Transmembrane currents were measured with an Axopatch-200 amplifier, a Digidata-1440 digitizer, and pClamp-10 software (Axon Instruments, Sunnyvale, CA), using the whole-cell patch-clamp technique. During an experiment, myocytes were superfused with a 36°C bath solution containing 135 mM NaCl, 4.6 mM CsCl, 1.8 mM CaCl 2 , 1.1 mM MgSO 4 , 0.01 mM nitrendipine, 0.3 mM BaCl 2 , 10 mM glucose, and 10 mM HEPES, pH 7.4. Nitrendipine, CsCl, and BaCl 2 were used to block L-type Ca 2ϩ and delayed-rectifier K ϩ channels, respectively. Ranolazine and TTX were applied to the bath solution. The recording pipettes were filled with a solution containing 120 mM cesium aspartate, 20 mM CsCl, 1 mM MgSO 4 , 4 mM Na 2 ATP, 0.1 mM Na 3 GTP, and 10 mM HEPES, pH 7.2. To activate late I Na , 300-ms voltage-clamp pulses from Ϫ90 to Ϫ50 mV at a frequency of 0.16 Hz were delivered to the cell through the patch pipette. Both the maximal amplitude (picoamperes) and integrated current (nC) of late I Na during the last 100 ms of a depolarizing pulse were calculated using pClamp software.
Data Collection and Statistical Analysis
LVEDP, CPP, and the electrocardiogram were monitored continuously during each isolated heart experiment and recorded using a Biopac recording unit with either Biopac Acqknowledge version 3.8.1 software or Notocord version 4.2 software (Notocord, Cherry Hill, NJ). Coronary resistance (in millimeters of mercury per milliliter per minute) was calculated as the ratio between CPP (in millimeters of mercury) and coronary perfusion rate (which was fixed at 10 ml/ min). Statistical analysis was performed using the software package Prism version 5.0 (GraphPad Software Inc., San Diego, CA). The significance of differences among isolated heart treatment group values was determined using two-way analysis of variance with repeated measures of one variable, unless stated otherwise. For analysis of data from myocyte electrophysiology experiments, the one-way repeated measures analysis of variance followed by Student-Newman-Keuls test for multiple comparisons was used. The percentage inhibition by ranolazine (Ran) of the effects of PC was calculated using the formula [(PC Ϫ Ran)/(PC Ϫ control)] ϫ 100, where PC, Ran, and control indicate measurements obtained in the presence of PC alone, PC plus Ran, and in the absence of drugs, respectively. Differences among measure values were considered to be significant when the probability of their chance occurrence was Ͻ0.05. Values of n indicate the number of cells or hearts studied. Data are expressed as mean Ϯ S.E.M.
Results
PC Increased
Late I Na and Ranolazine Attenuated the Effect of PC. The maximal amplitude of late I Na and the total late I Na during the last 100 ms of the clamp pulse (i.e., the integrated current) were significantly increased by PC (4 M, n ϭ 7) from Ϫ8.5 Ϯ 1.8 to Ϫ27.8 Ϯ 3.5 pA (p Ͻ 0.001) and from Ϫ0.352 Ϯ 0.078 to Ϫ2.611 Ϯ 0.242 nC (p Ͻ 0.001), respectively ( Fig. 1) . Ranolazine (10 M, n ϭ 7) reduced late I Na in the continuous presence of PC. The maximal amplitude of PC-induced late I Na and the total integrated current were reduced by ranolazine from Ϫ27.8 Ϯ 3.5 to Ϫ15.5 Ϯ 3.2 pA (p Ͻ 0.001) and from Ϫ2.611 Ϯ 0.242 to Ϫ1.486 Ϯ 0.200 nC (p Ͻ 0.001), respectively (Fig. 1) . In some experiments, after washout of ranolazine, cells were exposed to TTX (3 M, n ϭ 4) in the continued presence of PC. As shown in Fig. 1B , the PC-induced late current was completely inhibited by 3 M TTX, indicating that it was an Na ϩ current. Ranolazine Partially Reverses PC-Induced Cardiac Dysfunction. A 30-min treatment of the guinea pig isolated, perfused heart with 4 M PC led to increases of LVEDP, coronary resistance, lactate and adenosine release into the cardiac effluent, left-ventricular wall stiffness, and a de- Fig. 2 ) mm Hg. The PC-induced increase of LVEDP was not reversible during a 30-min washout period (Fig. 2) . Ranolazine (10 M) administration for 30 min significantly reversed the increase of LVEDP after PC treatment from 30 Ϯ 1.91 to 14 Ϯ 2.18 mm Hg (n ϭ 6, p Ͻ 0.001 compared with vehicle treatment) (Fig. 2) . Although much evidence indicates that the antianginal and cardioprotective effects of ranolazine are mediated by inhibition of late I Na (Hale et al., 2008) , ranolazine (10 M) also has been reported to reduce the hERG K ϩ (I Kr ) current in the heart (Antzelevitch et al., 2004) . Therefore, the effect of the selective, potent hERG blocker E-4031 to reverse a PC-induced increase of LVEDP was determined. Unlike ranolazine, E-4031 (10 nM) did not reverse the effect of PC to increase LVEDP (Fig. 2) .
Because an increase of LVEDP reduces the perfusion gradient for coronary flow and compresses microvessels, the effects of PC and ranolazine on coronary resistance were measured. Typical values of CPP in hearts perfused with drug-free K-H solution were 55 to 60 mm Hg, whereas in hearts perfused with K-H solution containing palmitoyl-Lcarnitine (4 M), values of CPP were typically 90 to 95 mm Hg. A 30-min exposure to 4 M PC increased coronary resistance from 5.82 Ϯ 0.21 to 9.24 Ϯ 0.39 mm Hg/ml/min (n ϭ 13; Fig. 3, top) . The effect of PC to elevate coronary resistance was not reversible upon washout of PC with vehicle (i.e., K-H solution) but was partially and significantly reversed by ranolazine (10 M, 30 min), from a value of 9.02 Ϯ 0.38 to 7.26 Ϯ 0.53 mm Hg/ml/min (n ϭ 7; Fig. 3 ). The Na ϩ channel blocker TTX (2 M; Fig. 3, top) , but not acetylcholine (10 M), esmolol (10 M), or sodium nitroprusside (30 M), significantly reversed the increase of coronary resistance caused by PC (Fig. 3, bottom) . TTX reduced coronary resistance from 9.40 Ϯ 0.43 (after 30-min treatment with PC) to 7.72 Ϯ 0.50 mm Hg/ml/min (n ϭ 6, p Ͻ 0.05; Fig. 3) . The endothelium-dependent vasodilator acetylcholine had no effect on coronary resistance after treatment of the heart with PC (Fig. 3) , whereas esmolol and sodium nitroprusside reduced coronary resistance slightly but not significantly from 9.14 Ϯ 0.27 to 8.64 Ϯ 0.17 and 9.69 Ϯ 0.68 to 8.32 Ϯ 0.29, respectively (n ϭ 5 each; p Ͼ 0.05 versus vehicle alone).
The release of lactate by the isolated perfused heart was also increased by PC. Lactate concentration in the cardiac effluent was increased from a control value of 0.028 Ϯ 0.002 to 0.133 Ϯ 0.006 mM (n ϭ 12, p Ͻ 0.001 versus no drug) after a 30-min exposure to 4 M PC (Fig. 4) . Ranolazine (10 M, 30 min) reduced the release of lactate by PC-treated hearts from 0.132 Ϯ 0.007 to 0.053 Ϯ 0.008 mM (n ϭ 6, p Ͻ 0.001 compared with vehicle alone; Fig. 4) . Likewise, the release of adenosine, another marker of an imbalance between oxygen supply and oxygen demand, from the perfused heart was increased by PC treatment, and the effect of PC was reversed by ranolazine (data not shown). When hearts were treated for 30 min with 4 M PC and then with either vehicle or ranolazine (10 M) for an additional 30 min, adenosine contents of the cardiac effluent were 26.3 Ϯ 9.4 and 3.6 Ϯ 1.5 ng/ml (n ϭ 6, p Ͻ 0.01), respectively. Left ventricular wall stiffness (i.e., the increase of LVEDP per increment of increase of LV volume) was also increased by PC, and this effect was significantly attenuated by ranolazine (Fig. 5) . Values of LVEDP at an intraventricular volume of 200 l were 90 Ϯ 7, 232 Ϯ 17, and 132 Ϯ 8 mm Hg in control, 4 M PC-treated, and PC ϩ ranolazine (10 M)-treated hearts, respectively (n ϭ 3 hearts each, p Ͻ 0.05; Fig. 5 ). The slope of the relationship between intraventricular volume and pressure was significantly steeper in hearts treated with palmitoyl-L-carnitine than in Treatment of hearts with ranolazine (10 M) or TTX (2 M) for 10 min before and during subsequent exposure to PC significantly but incompletely attenuated the effects of PC to increase LVEDP (Fig. 6 ) and coronary resistance (data not shown). The steady-state values of coronary resistance caused by a 30-min treatment with PC in the absence and presence of 10 M ranolazine were 9.47 Ϯ 0.72 and 6.94 Ϯ 0.16 mm Hg/ml/min, respectively (n ϭ 5-6, p Ͻ 0.01), whereas the value of coronary resistance before exposure to PC was 5.57 Ϯ 0.38 mm Hg/ml/min.
Tiron Pretreatment Reduced PC-Induced Cardiac Dysfunction. The oxygen free-radical scavenger tiron (1 mM) partially prevented the effect of PC to increase LVEDP (Fig. 7, top) . The combination of tiron (1 mM) and ranolazine (10 M) did not have a significantly greater effect than either ranolazine or tiron alone to reverse the action of PC on LVEDP (Fig. 7, top) . Unlike TTX and ranolazine, 1 mM tiron did not reverse the action of PC to increase LVEDP (Fig. 7, bottom). This suggests that tiron inhibits an early event (i.e., accumulation of reactive oxygen species) in a pathway leading to cardiac dysfunction but is unable to reverse events after reactive oxygen species have modified a target (e.g., an enhanced late I Na ) proximal to the rise in diastolic tension (LVEDP). This interpretation was supported by the results of experiments using guinea pig single isolated ventricular myocytes. When tiron (1 mM) was applied to myocytes that were first treated for 5 min with PC to increase late I Na , tiron did not reverse the PC-induced increase of late Na ϩ current (Fig. 8, A and B) . PC alone increased the maximal and late currents from Ϫ11.8 Ϯ 0.03 to Ϫ23.8 Ϯ 1.9 pA (p Ͻ 0.001; n ϭ 4) and from Ϫ0.535 Ϯ 0.055 to Ϫ1.810 Ϯ 0.212 nC (p Ͻ 0.001), respectively. After addition of tiron for 5 min, the maximal and integrated late currents were Ϫ22.5 Ϯ 2.9 pA (p Ͼ 0.05 versus PC) and Ϫ1.715 Ϯ 0.272 nC (p Ͼ 0.05 versus PC), respectively. In contrast, when tiron and PC were applied simultaneously for 5 min, the effect of PC to increase late I Na was significantly less than in the presence of PC alone (Fig. 8 , compare C and D with A and B), and after 5-min washout of tiron in the continued presence of PC, late current . 6 . Ranolazine or TTX administration before and during exposure of the guinea pig isolated heart to palmitoyl-L-carnitine (4 M) attenuated the effect of the latter to increase LVEDP. After an equilibration period of 10 min, hearts were treated with vehicle (n ϭ 6), TTX (2 M, n ϭ 4), or Ran (10 M, n ϭ 4) for 10 min, then with PC (4 M) for 30 min in the continued presence of vehicle, TTX, or ranolazine, and then with vehicle, TTX, or ranolazine in the absence of PC. Each point represents a mean Ϯ S.E.M. ‫,ء‬ p Ͻ 0.05; ‫,ءء‬ p Ͻ 0.01, compared with PC ϩ vehicle. increased further (Fig. 8C) . The effect of PC alone to increase myocyte late I Na was not readily reversed upon washout of PC (Fig. 8, E and F) .
Discussion
Palmitoyl-L-carnitine (4 M) increased the magnitude of late I Na in guinea pig ventricular myocytes and caused increases of coronary resistance, LVEDP, and left ventricular wall stiffness in the guinea pig isolated, electrically paced heart. Ranolazine reduced the PC-induced increase of late I Na in guinea pig myocytes (Fig. 1) and reduced PC-induced mechanical and metabolic dysfunction in the isolated, salineperfused heart (Figs. 2-7) . Because ranolazine, in addition to its action to reduce late I Na , is also known to reduce hERG K ϩ current (Antzelevitch et al., 2004) and is an antagonist of ␤-adrenergic receptors (Létienne et al., 2001) , the effects of the selective sodium channel antagonist TTX, the selective hERG inhibitor E-4031, and the ␤-adrenergic receptor blocker esmolol were tested in hearts treated with PC. Tetrodotoxin (2 M) significantly reversed the effects of PC to increase late I Na and coronary resistance. Because the only know action of tetrodotoxin is to decrease sodium flux through the voltage-regulated Na ϩ channel, the results are consistent with the view that many of the effects of PC are the result of its action to increase late I Na and that the protective effect of ranolazine is the result of its inhibition of late I Na . Consistent with this hypothesis, an increase of late I Na has been reported previously to cause mechanical, electrical, and metabolic dysfunction in the heart, and ranolazine is reported to reduce dysfunction in the setting of enhanced late I Na Hale et al., 2008) . Neither E-4031 nor esmolol reduced the effects of PC to increase LVEDP or coronary resistance, respectively (Figs. 2 and 3B) .
The free radical scavenger tiron also substantially prevented the effect of PC to increase LVEDP (Fig. 7) and late I Na (Fig. 8, C and D) , suggesting that an increased formation by PC of reactive oxygen species (ROS) may have played a significant role in the development of mechanical dysfunction in the PC-treated heart. However, unlike ranolazine, tiron did not reverse an elevation of LVEDP caused by PC (Fig. 7) , nor did it reduce the PC-enhanced late I Na (Fig. 8, A and B) . One interpretation of this finding is that an elevation of late I Na induced by ROS is not readily reversed by subsequent reduction of ROS formation but only by the direct inhibition of the ROS-mediated events, including an increase in Na ϩ channel current (late I Na ). ROS are known to increase late I Na in the heart (Ward and Giles, 1997; Ahern et al., 2000; Ma JH et al., 2005; Song et al., 2006; Gautier et al., 2008) and neurons (Meng and Nie, 2004) . Thus, the mechanisms underlying PC-induced cardiac mechanical dysfunction may involve sequential increases of ROS and late I Na . An increase of late I Na is a known cause of Na ϩ and Ca 2ϩ overload in the heart and is an explanation for the observed increases of LVEDP, coronary resistance, LV stiffness, and biochemical markers of ischemia, such as lactate and adenosine formation by isolated hearts in this study. This interpretation is consistent with the finding that lidocaine, another Na ϩ channel blocker, attenuated cardiac dysfunction caused by palmitoyl-L-carnitine .
The effect of ranolazine to attenuate an increase of coronary resistance caused by PC could be explained by at least two mechanisms. First, ranolazine could reduce or reverse the effect of PC to cause Na ϩ -induced Ca 2ϩ overload in the myocardium. Ca 2ϩ overload of the myocardium can lead to partial contracture of myocardial cells, an increase of ventricular stiffness and extravascular fluid pressure, compression of the vascular space, and an increase of coronary resistance. PC increased late I Na , LVEDP, LV stiffness (an indication of a failure of the heart to relax and, thus, a sign of the development of Ca 2ϩ overload contracture), and coro- jpet.aspetjournals.org nary resistance. Because PC increased coronary resistance, it is not surprising that it also increased lactate and adenosine release from the perfused heart. The availability of oxygen to the isolated heart perfused with oxygenated K-H solution is expected to be reduced when coronary resistance is increased because the increase of coronary resistance indicates reduced vascular volume (and, thus, reduced delivery of oxygen to the muscle cells). Thus, the increase by PC of lactate and adenosine release suggests that PC reduced availability of oxygen to the myocardium. In this scenario, ranolazine (and TTX) would reduce the PC-induced increase of Na ϩ entry and, thereby, the effects of PC on LVEDP, coronary resistance, and lactate release. Furthermore, vasodilators would fail to reduce the increase of coronary resistance caused by PC because the increase of coronary resistance would be caused by extravascular compression of capillaries and not by a change in vascular tone per se.
Palmitoyl-L-carnitine and ranolazine theoretically could modulate coronary perfusion pressure by actions directly on the vasculature (endothelium and vascular smooth muscle) to increase and decrease, respectively, vascular tone. PC was reported to cause a loss of vascular responsiveness to the endothelial-dependent vasodilator acetylcholine (Inoue et al., 1994; Taki et al., 1999) . We have confirmed this result. Hearts exposed to 4 M PC for 30 min were insensitive to 10 M acetylcholine (Fig. 3) . However, hearts treated with 4 M PC were somewhat responsive to sodium nitroprusside (Fig.  3) . This result suggests that it is not possible to disregard the possibility that PC has an action on the vessel wall to elevate coronary resistance and that ranolazine reverses this action. However, evidence that ranolazine directly relaxes vascular smooth muscle is currently lacking, whereas ranolazine did reduce LVEDP and left ventricular wall stiffness in this study. Consistent with this result, ranolazine was shown to reduce diastolic tension in electrically stimulated ventricular muscle strips from human failing hearts and to improve intracellular Ca 2ϩ handling in rabbit myocytes (Sossalla et al., 2008) . Thus, the effects of ranolazine and TTX to reverse the increase of coronary resistance caused by treatment of the heart with PC are most probably the result of actions of the two drugs to decrease sodium entry into myocardial cells and the resultant sequelae of Ca 2ϩ overload, impaired relaxation, increased extravascular pressure, and increased coronary resistance.
Ischemia is associated with an increase of late I Na (Ver Donck et al., 1993; Haigney et al., 1994; Le Grand et al., 1995; Ju et al., 1996; Hale et al., 2008) . The accumulation during ischemia of glycolytic metabolites (Kohlhardt et al., 1989) and the amphipathic lipids lysophosphatidylcholine and long-chain acyl carnitines (Sobel et al., 1978; DaTorre et al., 1991) appears to be at least partly responsible for causing the increase of late I Na during ischemia. There are several studies (see Gautier et al., 2008 , and references therein) demonstrating the effect of lysophosphatidylcholine to increase late I Na and cause cardiac electrical and mechanical dysfunction. The present report is the first to demonstrate that late I Na is increased by PC in cardiac myocytes, extending the results of two earlier studies suggesting the same (Shen and Pappano, 1995; Wu and Corr, 1995) . Although the effects of glycolytic and amphipathic lipid metabolites to cause Na ϩ channel, cellular, and organ dysfunction have been shown primarily in studies of cardiac tissues, these metabolites are likely to be part of the ischemic milieu in all tissues with Na ϩ channels. The content of long-chain acyl carnitines (including PC) increases in myocytes during hypoxia (DaTorre et al., 1991) , and these molecules are reported to accumulate in sarcolemmal membranes (Knabb et al., 1986) . Although the concentration of PC in ischemic myocardial cells has not been reported to our knowledge and the effects of endogenously produced and exogenously applied PC may be different, the concentration of 4 M PC used in this study is similar to concentrations used in previous studies (Mészà ros and Pappano, 1990; Sato et al., 1992; Wu and Corr, 1992; Shen and Pappano, 1995; Arakawa et al., 1997; Arakawa and Hara, 1999; Netticadan et al., 1999; Maruyama et al., 2000) , and the effects of an exogenous application of 4 M PC in this study are similar in magnitude to the effects of brief ischemia associated with a 4-to 5-fold elevation of long-chain acyl carnitine content in the heart (DaTorre et al., 1991) . Thus, the results of the present study suggest that a pathologically enhanced, PC-induced late I Na may be a contributor to ischemia-induced dysfunction.
